Literature DB >> 18048360

Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.

A Reza Radjabi1, Kenjiro Sawada, Sujatha Jagadeeswaran, Alfred Eichbichler, Hilary A Kenny, Anthony Montag, Katharina Bruno, Ernst Lengyel.   

Abstract

The procoagulatory serine protease, thrombin, is known to induce invasion and metastasis in various cancers, but the mechanisms by which it promotes tumorigenesis are poorly understood. Because the 92-kDa gelatinase (MMP-9) is a known mediator of tumor cell invasion, we sought to determine whether and how thrombin regulates MMP-9. The thrombin receptor, PAR-1, and MMP-9 are expressed in osteosarcomas, as determined by immunohistochemistry. Stimulation of U2-OS osteosarcoma cells with thrombin and a thrombin receptor-activating peptide induced pro-MMP-9 secretion as well as cell surface-associated pro-MMP-9 expression and proteolytic activity. This was paralleled by an increase in MMP-9 mRNA and MMP-9 promoter activity. Thrombin-induced invasion of U2-OS cells through Matrigel was mediated by the phosphatidylinositol 3-kinase signaling pathway and could be inhibited with an MMP-9 antibody. The stimulation of MMP-9 by thrombin was paralleled by an increase in beta1-integrin mRNA and beta1-integrin expression on the cell surface, which was also mediated by phosphatidylinositol 3-kinase and was required for invasion. Thrombin activation induced and co-localized both beta1-integrin and pro-MMP-9 on the cell membrane, as evidenced by co-immunoprecipitation, confocal microscopy, and a protein binding assay. The thrombin-mediated association of these two proteins, as well as thrombin-mediated invasion of U2-OS cells, could be blocked with a cyclic peptide and with an antibody preventing binding of the MMP-9 hemopexin domain to beta1-integrin. These results suggest that thrombin induces expression and association of beta1-integrin with MMP-9 and that the cell surface localization of the protease by the integrin promotes tumor cell invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048360      PMCID: PMC2805198          DOI: 10.1074/jbc.M704855200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin.

Authors:  S C Even-Ram; M Maoz; E Pokroy; R Reich; B Z Katz; P Gutwein; P Altevogt; R Bar-Shavit
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

Review 2.  Reciprocal interactions between adhesion receptor signaling and MMP regulation.

Authors:  H G Munshi; M S Stack
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

3.  Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1.

Authors:  M W Olson; M M Bernardo; M Pietila; D C Gervasi; M Toth; L P Kotra; I Massova; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

Review 4.  Effect of anticoagulant drugs in cancer.

Authors:  Anna Falanga; Andrea Piccioli
Journal:  Curr Opin Pulm Med       Date:  2005-09       Impact factor: 3.155

5.  The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity.

Authors:  M Morini; M Mottolese; N Ferrari; F Ghiorzo; S Buglioni; R Mortarini; D M Noonan; P G Natali; A Albini
Journal:  Int J Cancer       Date:  2000-08-01       Impact factor: 7.396

Review 6.  Thrombin signalling and protease-activated receptors.

Authors:  S R Coughlin
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

7.  Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

Authors:  S M Ellerbroek; J M Halbleib; M Benavidez; J K Warmka; E V Wattenberg; M S Stack; L G Hudson
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

8.  Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.

Authors:  Sorina Grisaru-Granovsky; Zaidoun Salah; Myriam Maoz; Diana Pruss; Uziel Beller; Rachel Bar-Shavit
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

9.  C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.

Authors:  Ernst Lengyel; Dieter Prechtel; James H Resau; Katja Gauger; Anita Welk; Kristina Lindemann; Georgia Salanti; Thomas Richter; Beatrice Knudsen; George F Vande Woude; Nadia Harbeck
Journal:  Int J Cancer       Date:  2005-02-10       Impact factor: 7.396

10.  Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.

Authors:  Ying Wei; Ralf-Peter Czekay; Liliane Robillard; Matthias C Kugler; Feng Zhang; Kevin K Kim; Jian-Ping Xiong; Martin J Humphries; Harold A Chapman
Journal:  J Cell Biol       Date:  2005-01-31       Impact factor: 10.539

View more
  31 in total

1.  ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.

Authors:  Sonali Ghosh; Moitri Basu; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

2.  MMP9 cleavage of the β4 integrin ectodomain leads to recurrent epithelial erosions in mice.

Authors:  Sonali Pal-Ghosh; Tomas Blanco; Gauri Tadvalkar; Ahdeah Pajoohesh-Ganji; Arpitha Parthasarathy; James D Zieske; Mary Ann Stepp
Journal:  J Cell Sci       Date:  2011-07-12       Impact factor: 5.285

3.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

4.  Visualizing correlated motion with HDBSCAN clustering.

Authors:  Ryan L Melvin; Jiajie Xiao; Ryan C Godwin; Kenneth S Berenhaut; Freddie R Salsbury
Journal:  Protein Sci       Date:  2017-09-06       Impact factor: 6.725

5.  Monoclonal Antibody Targeting the Matrix Metalloproteinase 9 Prevents and Reverses Paclitaxel-Induced Peripheral Neuropathy in Mice.

Authors:  Raquel Tonello; Sang Hoon Lee; Temugin Berta
Journal:  J Pain       Date:  2018-11-22       Impact factor: 5.820

6.  Matrix metalloproteinase-9 inhibition reduces inflammation and improves motility in murine models of postoperative ileus.

Authors:  Beverley A Moore; Carl L Manthey; Dana L Johnson; Anthony J Bauer
Journal:  Gastroenterology       Date:  2011-06-22       Impact factor: 22.682

7.  Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.

Authors:  Silvio Antoniak; Kohei Tatsumi; Clare M Schmedes; Steven P Grover; Rafal Pawlinski; Nigel Mackman
Journal:  J Mol Cell Cardiol       Date:  2018-08-10       Impact factor: 5.000

8.  Mechanistic insights into thrombin's switch between "slow" and "fast" forms.

Authors:  Jiajie Xiao; Ryan L Melvin; Freddie R Salsbury
Journal:  Phys Chem Chem Phys       Date:  2017-09-20       Impact factor: 3.676

9.  Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning.

Authors:  Jiajie Xiao; Ryan L Melvin; Freddie R Salsbury
Journal:  J Biomol Struct Dyn       Date:  2018-03-02

Review 10.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.